Viewing Study NCT07279402

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:39 AM
Ignite Modification Date: 2026-03-09 @ 2:28 AM
Study NCT ID: NCT07279402
Status: RECRUITING
Last Update Posted: 2025-12-12
First Post: 2025-12-01
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Sponsor: Antalya Training and Research Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None NSCLC Stage IV View
None PD-L1 Gene Mutation View
None Atezolizumab View
None Real World Study View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NSCLC, PD-L1, Atezolizumab, Real World View